Dr. Christopher J. Kane, MD

Dr. Kane practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Kane's NPI, 1083636294, was assigned on July 24, 2006. Dr. Kane graduated from Uniformed Services University, F. Edward Hebert School of Medicine in 1989. Dr. Kane holds California license G69249.

Dr. Kane's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Kane's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Kane is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kane practices. Vendor and product names are available with a free account.

Urology is Dr. Kane's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Kane is board certified in urology by the American Board of Urology. Dr. Kane is licensed in California.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney removal surgery, prostate cancer, prostate inflammation or infection, prostate surgery and urinary endoscopy among the conditions Dr. Kane treats.

CMS data shows 29,278 Medicare services from Dr. Kane across 11 procedure codes in 2024, for 13,958 Medicare patients. Medicare paid $301,696 for them.

CMS counts 13,958 Medicare patients who saw Dr. Kane in 2024. The largest group is 65 to 74, with 5,964 patients. 72% of them have high cholesterol, and 69% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kane's median patient age at 55, with 57% women.

In 2024, Dr. Kane wrote 56 Medicare Part D claims for 40 patients. 95% of them were for generic drugs. CMS names the drug for 34 of them, across 2 drugs with 11 or more claims each, at $314 in total drug cost. In 2023, CMS named 58 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Kane for performance year 2024, reported as part of a group. Dr. Kane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kane as offering telehealth. CMS counts 24 procedures of prostate resection by Dr. Kane, more than 86% of the clinicians it reports for that procedure.

Hernia repair (minimally invasive): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 193 papers to Dr. Kane, published from 2007 to 2025. 2021 was the busiest year, with 10. The most frequent topics are Prostatic Neoplasms, Prostatectomy and Kidney Neoplasms. Dr. Kane has published most often in Urology. Dr. Kane's most frequent co-authors are Peter R. Carroll, MD, John Kellogg Parsons, MD and Michael Andre Liss, MD.

Dmand AI links Dr. Kane to 2 clinical trials. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 67 general payments to Dr. Kane from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Janssen Pharmaceuticals, Inc paid the most, $14,447.

Dmand AI lists 39 awards for Dr. Kane, most recently San Diego Magazine Top Doctors in 2016.

Dr. Kane graduated from Uniformed Services University, F. Edward Hebert School of Medicine in 1989. Dr. Kane is a member of ACS and AUA.

Dr. Kane is in network with 16 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.